Global Prevalence of Prediabetes
Diabetes Care · 01.07.2023 · 46 (7) · 1388-1394
DOI: 10.2337/dc22-2376 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes Care, online erschienen am 17.05.2023. Verfasst von Mary R Rooney und 7 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Epidemiology and Welch Center for Prevention, Epidemiology, & Clinical Research, Johns Hopkins Bloomberg School of Public Health, Balt…. Hauptthemen laut MEDLINE: Glucose Intolerance, Prediabetic State. Die Arbeit wurde bisher 515-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Novo Nordisk, Sanofi.
Abstract (Originalsprache)
OBJECTIVE To estimate the global, regional, and national prevalence of prediabetes, defined by impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). RESEARCH DESIGN AND METHODS We reviewed 7,014 publications for high-quality estimates of IGT (2-h glucose, 7.8–11.0 mmol/L [140–199 mg/dL]) and IFG (fasting glucose, 6.1–6.9 mmol/L [110–125 mg/dL]) prevalence for each country. We used logistic regression to generate prevalence estimates for IGT and IFG among adults aged 20–79 years in 2021 and projections for 2045. For countries without in-country data, we extrapolated estimates from countries with available data with similar geography, income, ethnicity, and language. Estimates were standardized to the age distribution for each country from the United Nations. RESULTS Approximately two-thirds of countries did not have high-quality IGT or IFG data. There were 50 high-quality studies for IGT from 43 countries and 43 high-quality studies for IFG from 40 countries. Eleven countries had data for both IGT and IFG. The global prevalence of IGT in 2021 was 9.1% (464 million) and is projected to increase to 10.0% (638 million) in 2045. The global prevalence of IFG in 2021 was 5.8% (298 million) and is projected to increase to 6.5% (414 million) in 2045. The 2021 prevalence of IGT and IFG was highest in high-income countries. In 2045, the largest relative growth in cases of IGT and IFG would be in low-income countries. CONCLUSIONS The global burden of prediabetes is substantial and growing. Enhancing prediabetes surveillance is necessary to effectively implement diabetes prevention policies and interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Department of Epidemiology and Welch Center for Prevention, Epidemiology, & Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
- 2Environmental Epidemiology Group, Institute of Occupational, Social and Environmental Medicine, Centre for Health and Society, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, D…
- 3Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, Baltimore, MD.
- 4Seattle Epidemiologic Research and Information Center, VA Puget Sound Health Care System, Seattle, WA.
- 5Baker Heart and Diabetes Institute & School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
ORCID-Profile: Mary R Rooney, Michael Fang, Justin B Echouffo-Tcheugui, Edward J Boyko, Dianna J Magliano, Elizabeth Selvin
Förderung
- NHLBI NIH HHS
- Novo Nordisk
- Sanofi
- Pfizer-MSD Alliance
Zitieren
APA
Rooney, M. R., Fang, M., Ogurtsova, K., Ozkan, B., Echouffo-Tcheugui, J. B., Boyko, E. J., Magliano, D. J., & Selvin, E. (2023). Global Prevalence of Prediabetes. Diabetes Care, 46(7), 1388-1394. https://doi.org/10.2337/dc22-2376
Vancouver
Rooney MR, Fang M, Ogurtsova K, Ozkan B, Echouffo-Tcheugui JB, Boyko EJ, et al. Global Prevalence of Prediabetes. Diabetes Care. 2023;46(7):1388-1394. doi:10.2337/dc22-2376
BibTeX
@article{Rooney2023,
author = {Rooney, Mary R and Fang, Michael and Ogurtsova, Katherine and Ozkan, Bige and Echouffo-Tcheugui, Justin B and Boyko, Edward J and Magliano, Dianna J and Selvin, Elizabeth},
title = {Global Prevalence of Prediabetes},
journal = {Diabetes Care},
year = {2023},
volume = {46},
number = {7},
pages = {1388--1394},
doi = {10.2337/dc22-2376}
}
EUVIMED